Invivyd surged after reporting its antibodies pemivibart and VYD2311 neutralized the new XFG COVID-19 variant in lab tests, with no resistant strains found. The FDA also agreed to a streamlined path for VYD2311 approval via a single Phase 2/3 trial. Retail chatter spiked 175%, with sentiment turning bullish as shares gained 16%.